2-butylaminoethanol

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics

Type of information:

other: expert statement

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: An extended assessment of the toxicokinetic behaviour of butylethanolamine was performed, taking into account the chemical structure, the available physico-chemical data and the available toxicity data.

Data source

Reference

Reference 1

Reference Type:

other: Expert statement

Title:

Unnamed

Year:

2013

Report date:

2013

Reference 2

Reference Type:

other: prediction by the OECD QSAR Toolbox

Title:

Unnamed

Year:

2013

Report date:

2013

Materials and methods

Objective of study:

absorption

distribution

excretion

metabolism

Test guideline

Qualifier:

according to guideline

Guideline:

other: expert statement according to the TGD, Part I, Annex IV, 2003); ECHA Guidance R7c., 2008

Deviations:

no

Principles of method if other than guideline:

An assessment of toxicological behaviour of butylethanolamine is based on its physico-chemical properties and on the results of available toxicity data data.

GLP compliance:

no

Test material

Test material information

Constituent 1

Reference substance name:

2-butylaminoethanol

EC Number:

203-904-5

EC Name:

2-butylaminoethanol

Cas Number:

111-75-1

Molecular formula:

C6H15NO

IUPAC Name:

2-(butylamino)ethan-1-ol

Constituent 2

Reference substance name:

Butylethanolamine

IUPAC Name:

Butylethanolamine

Test material form:

other: liquid

Details on test material:

- Name of test material (as cited in study report): Butylethanolamine

Radiolabelling:

no

Results and discussion

Main ADME results

Main ADME results 1

Type:

absorption

Results:

BEA is expected to be absorbed from GI tract by passive diffusion. A high systemic availability via dermal and inhalation routes is unlikely.

Main ADME results 2

Type:

distribution

Results:

BEA is expected to be predominantly distributed into the intravascular compartment due to its MW of 117.2 g/mol and high water solubility. BEA can also enter the cell inner (LogPow of 0.64). No risk for accumulation is expected for BEA (LogPow is <3.0).

Main ADME results 3

Type:

metabolism

Results:

Hydroxylation and oxidation reactions by Phase I enzymes; conjugation reactions.

Main ADME results 4

Type:

excretion

Results:

BEA is expected to be excreted primarily via the urine due to its MW (117.2 g/mol), vapour pressure (13.94 Pa) and high water solubility (1000 g/L).

Metabolite characterisation studies

Metabolites identified:

yes

Details on metabolites:

Derivatives of hydroxilation and oxidation reactions.

Applicant's summary and conclusion

Conclusions:

Interpretation of results: no bioaccumulation potential based on study results
No bioaccumulation potential for BEA.

Executive summary:

An assessment of the toxicokinetic behaviour of butylethanolamine was performed, taking into account the chemical structure, the available physico-chemical-data and the available toxicity data. BEA is expected to be absorbed from GI tract by passive diffusion. A high systemic availability via dermal and inhalation routes is unlikely. BEA is expected to be predominantly distributed into the intravascular compartment due to its MW of 117.2 g/mol and high water solubility (1000 g/L). BEA can also enter the cell inner (LogPow of 0.62). No risk for accumulation is expected for BEA (LogPow is < 3.0). Possible reactions: hydroxylation and oxidation by Phase I enzymes with subsequent conjugation reactions. BEA is expected to be excreted primarily via the urine due to it MW (117.2 g/mol), vapour pressure (13.94 Pa) and the high water solubility (1000 g/L).